CV Advisors
VRTX icon

CV Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

CV Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.67M Hold
3,200
– – 0.28% 33
2026
Q2 		$1.59M Buy
+3,200
New +$1.42M 0.29% 39

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
AMF Tjänstepension
AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Davenport & Co
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Montrusco Bolton Investments
Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return
Birch Hill Investment Advisors
Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return
Asset Management One
Asset Management One Tokyo, Japan $40B AUM 30.45% 1-Year Est. Return

CV Advisors's VRTX Position: Q3 2026 in Review

CV Advisors held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2026 at 3,200 shares worth $1.67M. The position accounts for 0.28% of the portfolio, ranked #33.

CV Advisors first reported a position in VRTX in Q2 2026 and has held it in 2 quarters since. 553 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • CV Advisors held 3,200 shares of Vertex Pharmaceuticals worth $1.67M as of Q3 2026.
  • CV Advisors left its Vertex Pharmaceuticals share count unchanged in Q3 2026.
  • Vertex Pharmaceuticals made up 0.28% of CV Advisors's portfolio in Q3 2026, its #33 holding.
  • CV Advisors first reported a position in Vertex Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • 553 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on CV Advisors's 13F filing for Q3 2026, filed 13 Oct 2026.